World's Best Scientists 2026 revealed!

Overview

Eric L. Simpson is affiliated with Oregon Health & Science University in the United States. Their research primarily focuses on the field of medicine with a strong emphasis on dermatology and related areas.

The main fields of study covered in their work include:

  • Medicine

Within this broader domain, their research spans several subfields such as:

  • Dermatology
  • Immunology and Allergy
  • Physiology
  • Rheumatology
  • Immunology

The principal topics of their work are:

  • Dermatology and Skin Diseases
  • Allergic Rhinitis and Sensitization
  • Food Allergy and Anaphylaxis Research
  • Asthma and respiratory diseases
  • Urticaria and Related Conditions
  • Transgenic Plants and Applications
  • IL-33, ST2, and ILC Pathways

Frequent co-authors collaborating with Eric L. Simpson include:

  • Jonathan I. Silverberg
  • Lawrence F. Eichenfield
  • Andrew Blauvelt
  • Amy S. Paller
  • Emma Guttman-Yassky

Their work has been published in several key venues, notable for the number of papers they contributed:

  • Journal of the American Academy of Dermatology
  • British Journal of Dermatology
  • SKIN The Journal of Cutaneous Medicine
  • Journal of Investigative Dermatology
  • Dermatology and Therapy

Some recent significant papers by Eric L. Simpson include:

  • Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1), 2020, The Lancet
  • Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2), 2021, The Lancet
  • Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2), 2020, British Journal of Dermatology
  • Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis, 2021, JAMA Dermatology
  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis, 2021, New England Journal of Medicine

Best Publications

  • Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    Andrew Blauvelt;Marjolein de Bruin-Weller;Melinda Gooderham;Jennifer C. Cather

  • Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

    Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  • Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study

    Jonathan I. Silverberg;Joel M. Gelfand;David J. Margolis;Mark Boguniewicz

  • Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

    A. Wollenberg;A. Blauvelt;E. Guttman‐Yassky;M. Worm

  • Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.

    Eric L. Simpson;Amy S. Paller;Elaine C. Siegfried;Mark Boguniewicz

  • Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

    Emma Guttman-Yassky;Henrique D. Teixeira;Eric L. Simpson;Kim A. Papp

  • Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

    Eric L Simpson;Rodney Sinclair;Seth Forman;Andreas Wollenberg

  • Conjunctivitis in dupilumab clinical trials.

    B. Akinlade;E. Guttman-Yassky;M. de Bruin-Weller;E. L. Simpson

  • Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study

    Jonathan I. Silverberg;Sebastien Barbarot;Abhijit Gadkari;Eric L. Simpson

  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

    Thomas Bieber;Eric L. Simpson;Jonathan I. Silverberg;Diamant Thaçi

  • Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

    Eric L. Simpson;J.‐P. Lacour;L. Spelman;R. Galimberti

  • Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).

    Eric L. Simpson;Carsten Flohr;Lawrence F. Eichenfield;Thomas Bieber

  • Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.

    Jonathan I. Silverberg;Eric L. Simpson;Jacob P. Thyssen;Melinda J. Gooderham

  • Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population

    Zelma C. Chiesa Fuxench;Julie K. Block;Mark Boguniewicz;John Boyle

  • Efficacy and Safety of Upadacitinib vs Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

    Andrew Blauvelt;Henrique D. Teixeira;Eric L. Simpson;Antonio Costanzo

  • Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial

    Emma Guttman-Yassky;Andrew Blauvelt;Lawrence F. Eichenfield;Lawrence F. Eichenfield;Amy S. Paller

  • Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial

    Joanne R Chalmers;Rachel H Haines;Lucy E Bradshaw;Alan A Montgomery

  • Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.

    Eric L. Simpson;Jane R. Parnes;Dewei She;Sarah Crouch

  • What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study.

    Y.A. Leshem;T. Hajar;J.M. Hanifin;E.L. Simpson

  • Persistence of atopic dermatitis (AD): A systematic review and meta-analysis

    Jooho P. Kim;Lucy X. Chao;Eric L. Simpson;Jonathan I. Silverberg

Frequent Co-Authors

Jonathan I. Silverberg
Jonathan I. Silverberg George Washington University Hospital
Lawrence F. Eichenfield
Lawrence F. Eichenfield University of California, San Diego
Mark Boguniewicz
Mark Boguniewicz National Jewish Health
Emma Guttman-Yassky
Emma Guttman-Yassky Icahn School of Medicine at Mount Sinai
Jon M. Hanifin
Jon M. Hanifin Oregon Health & Science University
Lisa A. Beck
Lisa A. Beck University of Rochester Medical Center
David J. Margolis
David J. Margolis University of Pennsylvania
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Hywel C. Williams
Hywel C. Williams University of Nottingham
Joel M. Gelfand
Joel M. Gelfand University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but want alternative pathways or supporting degrees, there are several excellent online options to explore. For those interested in the administrative side of healthcare, pursuing an accelerated healthcare administration degree can prepare you for management roles in hospitals and clinics, often in less time than traditional programs.

If patient care is your passion but you’re looking for a flexible or quicker entry point, you might consider the lpn to rn programs without teas test, ideal for licensed practical nurses wanting to become registered nurses without additional standardized testing obstacles.

Medical billing and coding is another essential healthcare field that offers remote job opportunities. Many accredited medical billing and coding schools online with financial aid make it easier to start this career while managing costs.

Lastly, registered nurses aiming to advance their education can benefit from bridge programs such as the rn to np route, helping RNs become nurse practitioners through streamlined online study options.

Best Scientists Citing Eric L. Simpson

Trending Scientists

Recently Published Articles